Madam Chair and honourable members of the committee, on behalf of Hoffmann-La Roche, we want to thank you for the opportunity to speak today. We applaud the efforts of the federal government and of front-line health care workers to combat the spread of COVID-19 and to protect our economy.
Roche is a global pharmaceutical and diagnostics company focused on advancing in science and improving health outcomes for patients. Our combined strengths have made Roche a leader in personalized health care, a strategy that aims to tailor the right treatment to the right patient at the right time.
In 2019 we invested $284 million in research and development, with $57 million in clinical research in Canada. Most recently we announced a $500-million investment over five years to establish a global site, bringing up to 500 highly specialized jobs to Mississauga.
There are a number of initiatives Roche is working on to address some of the challenges associated with the pandemic. Phase three clinical trials are under way to study the safety and efficacy of one of our medications in hospitalized adult patients with severe COVID-19 pneumonia. On the diagnostics front, our molecular test was approved under Health Canada's special access program and contributes to a significant portion of testing across Canada. We have also submitted our antibody test for approval, which we are expecting shortly. We are very pleased about the potential of this test as we begin to move into the recovery phase and engage with the COVID-19 immunity task force to combine our efforts.
Another initiative we're very proud of is our open innovation challenge, a funding program supporting ideas, addressing some of the biggest challenges of the pandemic. After receiving more than 800 submissions from across the health sciences and technology community in Canada, we're excited to help develop and implement 11 of those ideas. One looks at testing climate conditions on COVID-19 transmission through an aerosol chamber designed by a team of virologists and engineers. Another project uses real-time artificial intelligence to track, monitor and predict symptoms among high-risk seniors.
We've also assembled the Roche data science coalition, a group of academic and private organizations with a common mission. This coalition endorses grassroots challenge identification, access to data and the development of actionable insights related to the pandemic. Our collaborators include Self Care Catalysts, ThinkData Works, Amii, the Vector Institute and experts in privacy. Over the last eight weeks we have secured five to seven years' worth of global partnerships and have developed over 100 artificial intelligence solutions, virtual dashboards, market reports and overall deeper partnerships with stakeholders across the globe.